In 2021, Serum Institute of India Pvt. Ltd. subsidiary Serum Institute of Life Sciences (SILS) entered a deal with Biocon, Ltd. arm Biocon Biologics to acquire a 15% stake in exchange for a $150m cash infusion and access to a vaccine pipeline that would have included COVID-19 and other vaccines.
Serum-Biocon Deal Sees COVID Reality Tweak Even As Oxford’s Malaria Vaccine Holds Promise
HPV Vaccine India Tender Keenly Awaited
Gains from its COVID-19 vaccine made Serum Institute’s founder the world’s richest healthcare billionaire. But the demand for boosters hasn’t materialized as expected, leading to a deal with Biocon being tweaked. Meanwhile, gains from India’s first indigenously-developed HPV vaccine and Oxford-partnered malaria vaccine seem imminent.
